Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Mariam Jamal-Hanjani; Alan Hackshaw; Yenting Ngai; Jacqueline Shaw; Caroline Dive; Sergio Quezada; Gary Middleton; Elza de Bruin; John Le Quesne; Seema Shafi; Mary Falzon; Stuart Horswell; Fiona Blackhall; Iftekhar Khan; Sam Janes; Marianne Nicolson; David Lawrence; Martin Forster; Dean Fennell; Siow Ming Lee; Jason Lester; Keith Kerr; Salli Muller; Natasha Iles; Sean Smith; Nirupa Murugaesu; Richard Mitter; Max Salm; Aengus Stuart; Nik Matthews; Haydn Adams; Tanya Ahmad; Richard Attanoos; Jonathan Bennett; Nicolai Juul Birkbak; Richard Booton; Ged Brady; Keith Buchan; Arrigo Capitano; Mahendran Chetty; Mark Cobbold; Philip Crosbie; Helen Davies; Alan Denison; Madhav Djearman; Jacki Goldman; Tom Haswell; Leena Joseph; Malgorzata Kornaszewska; Matthew Krebs; Gerald Langman; Mairead MacKenzie; Joy Millar; Bruno Morgan; Babu Naidu; Daisuke Nonaka; Karl Peggs; Catrin Pritchard; Hardy Remmen; Andrew Rowan; Rajesh Shah; Elaine Smith; Yvonne Summers; Magali Taylor; Selvaraju Veeriah; David Waller; Ben Wilcox; Maggie Wilcox; Ian Woolhouse; Nicholas McGranahan; Charles Swanton

doi:10.1371/journal.pbio.1001906

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Mariam Jamal-Hanjani
, Alan Hackshaw
, Yenting Ngai
, Jacqueline Shaw
, Caroline Dive
, Sergio Quezada
, Gary Middleton
, Elza de Bruin
, John Le Quesne
, Seema Shafi
, Mary Falzon
, Stuart Horswell
, Fiona Blackhall
, Iftekhar Khan
, Sam Janes
, Marianne Nicolson
, David Lawrence
, Martin Forster
, Dean Fennell
, Siow Ming Lee

Jason Lester, Keith Kerr, Salli Muller, Natasha Iles, Sean Smith, Nirupa Murugaesu, Richard Mitter, Max Salm, Aengus Stuart, Nik Matthews, Haydn Adams, Tanya Ahmad, Richard Attanoos, Jonathan Bennett, Nicolai Juul Birkbak, Richard Booton, Ged Brady, Keith Buchan, Arrigo Capitano, Mahendran Chetty, Mark Cobbold, Philip Crosbie, Helen Davies, Alan Denison, Madhav Djearman, Jacki Goldman, Tom Haswell, Leena Joseph, Malgorzata Kornaszewska, Matthew Krebs, Gerald Langman, Mairead MacKenzie, Joy Millar, Bruno Morgan, Babu Naidu, Daisuke Nonaka, Karl Peggs, Catrin Pritchard, Hardy Remmen, Andrew Rowan, Rajesh Shah, Elaine Smith, Yvonne Summers, Magali Taylor, Selvaraju Veeriah, David Waller, Ben Wilcox, Maggie Wilcox, Ian Woolhouse, Nicholas McGranahan, Charles Swanton^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

190 Citations (Scopus)

15 Downloads (Pure)

Abstract

The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

Original language	English
Article number	e1001906
Pages (from-to)	1-7
Number of pages	7
Journal	PLoS Biology
Volume	12
Issue number	7
DOIs	https://doi.org/10.1371/journal.pbio.1001906
Publication status	Published - 8 Jul 2014

Bibliographical note

This study is primarily funded by Cancer Research UK, but has also received funding from the Rosetrees Trust, the Academy of Medical Sciences, and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1371/journal.pbio.1001906Licence: CC BY

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
© 2014 Jamal-Hanjani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. https://creativecommons.org/licenses/by/4.0/
Final published version, 701 KBLicence: CC BY

Cite this

Jamal-Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S., Middleton, G., de Bruin, E., Le Quesne, J., Shafi, S., Falzon, M., Horswell, S., Blackhall, F., Khan, I., Janes, S., Nicolson, M., Lawrence, D., Forster, M., Fennell, D., ... Swanton, C. (2014). Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 12(7), 1-7. Article e1001906. https://doi.org/10.1371/journal.pbio.1001906

Jamal-Hanjani, M, Hackshaw, A, Ngai, Y, Shaw, J, Dive, C, Quezada, S, Middleton, G, de Bruin, E, Le Quesne, J, Shafi, S, Falzon, M, Horswell, S, Blackhall, F, Khan, I, Janes, S, Nicolson, M, Lawrence, D, Forster, M, Fennell, D, Lee, SM, Lester, J, Kerr, K, Muller, S, Iles, N, Smith, S, Murugaesu, N, Mitter, R, Salm, M, Stuart, A, Matthews, N, Adams, H, Ahmad, T, Attanoos, R, Bennett, J, Birkbak, NJ, Booton, R, Brady, G, Buchan, K, Capitano, A, Chetty, M, Cobbold, M, Crosbie, P, Davies, H, Denison, A, Djearman, M, Goldman, J, Haswell, T, Joseph, L, Kornaszewska, M, Krebs, M, Langman, G, MacKenzie, M, Millar, J, Morgan, B, Naidu, B, Nonaka, D, Peggs, K, Pritchard, C, Remmen, H, Rowan, A, Shah, R, Smith, E, Summers, Y, Taylor, M, Veeriah, S, Waller, D, Wilcox, B, Wilcox, M, Woolhouse, I, McGranahan, N & Swanton, C 2014, 'Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study', PLoS Biology, vol. 12, no. 7, e1001906, pp. 1-7. https://doi.org/10.1371/journal.pbio.1001906

@article{2e159a4425f443328dcbf3fa3976ddb5,

title = "Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study",

abstract = "The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.",

author = "Mariam Jamal-Hanjani and Alan Hackshaw and Yenting Ngai and Jacqueline Shaw and Caroline Dive and Sergio Quezada and Gary Middleton and \{de Bruin\}, Elza and \{Le Quesne\}, John and Seema Shafi and Mary Falzon and Stuart Horswell and Fiona Blackhall and Iftekhar Khan and Sam Janes and Marianne Nicolson and David Lawrence and Martin Forster and Dean Fennell and Lee, \{Siow Ming\} and Jason Lester and Keith Kerr and Salli Muller and Natasha Iles and Sean Smith and Nirupa Murugaesu and Richard Mitter and Max Salm and Aengus Stuart and Nik Matthews and Haydn Adams and Tanya Ahmad and Richard Attanoos and Jonathan Bennett and Birkbak, \{Nicolai Juul\} and Richard Booton and Ged Brady and Keith Buchan and Arrigo Capitano and Mahendran Chetty and Mark Cobbold and Philip Crosbie and Helen Davies and Alan Denison and Madhav Djearman and Jacki Goldman and Tom Haswell and Leena Joseph and Malgorzata Kornaszewska and Matthew Krebs and Gerald Langman and Mairead MacKenzie and Joy Millar and Bruno Morgan and Babu Naidu and Daisuke Nonaka and Karl Peggs and Catrin Pritchard and Hardy Remmen and Andrew Rowan and Rajesh Shah and Elaine Smith and Yvonne Summers and Magali Taylor and Selvaraju Veeriah and David Waller and Ben Wilcox and Maggie Wilcox and Ian Woolhouse and Nicholas McGranahan and Charles Swanton",

note = "This study is primarily funded by Cancer Research UK, but has also received funding from the Rosetrees Trust, the Academy of Medical Sciences, and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",

year = "2014",

month = jul,

day = "8",

doi = "10.1371/journal.pbio.1001906",

language = "English",

volume = "12",

pages = "1--7",

journal = "PLoS Biology",

issn = "1544-9173",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - Tracking Genomic Cancer Evolution for Precision Medicine

T2 - The Lung TRACERx Study

AU - Jamal-Hanjani, Mariam

AU - Hackshaw, Alan

AU - Ngai, Yenting

AU - Shaw, Jacqueline

AU - Dive, Caroline

AU - Quezada, Sergio

AU - Middleton, Gary

AU - de Bruin, Elza

AU - Le Quesne, John

AU - Shafi, Seema

AU - Falzon, Mary

AU - Horswell, Stuart

AU - Blackhall, Fiona

AU - Khan, Iftekhar

AU - Janes, Sam

AU - Nicolson, Marianne

AU - Lawrence, David

AU - Forster, Martin

AU - Fennell, Dean

AU - Lee, Siow Ming

AU - Lester, Jason

AU - Kerr, Keith

AU - Muller, Salli

AU - Iles, Natasha

AU - Smith, Sean

AU - Murugaesu, Nirupa

AU - Mitter, Richard

AU - Salm, Max

AU - Stuart, Aengus

AU - Matthews, Nik

AU - Adams, Haydn

AU - Ahmad, Tanya

AU - Attanoos, Richard

AU - Bennett, Jonathan

AU - Birkbak, Nicolai Juul

AU - Booton, Richard

AU - Brady, Ged

AU - Buchan, Keith

AU - Capitano, Arrigo

AU - Chetty, Mahendran

AU - Cobbold, Mark

AU - Crosbie, Philip

AU - Davies, Helen

AU - Denison, Alan

AU - Djearman, Madhav

AU - Goldman, Jacki

AU - Haswell, Tom

AU - Joseph, Leena

AU - Kornaszewska, Malgorzata

AU - Krebs, Matthew

AU - Langman, Gerald

AU - MacKenzie, Mairead

AU - Millar, Joy

AU - Morgan, Bruno

AU - Naidu, Babu

AU - Nonaka, Daisuke

AU - Peggs, Karl

AU - Pritchard, Catrin

AU - Remmen, Hardy

AU - Rowan, Andrew

AU - Shah, Rajesh

AU - Smith, Elaine

AU - Summers, Yvonne

AU - Taylor, Magali

AU - Veeriah, Selvaraju

AU - Waller, David

AU - Wilcox, Ben

AU - Wilcox, Maggie

AU - Woolhouse, Ian

AU - McGranahan, Nicholas

AU - Swanton, Charles

N1 - This study is primarily funded by Cancer Research UK, but has also received funding from the Rosetrees Trust, the Academy of Medical Sciences, and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2014/7/8

Y1 - 2014/7/8

N2 - The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

AB - The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

UR - https://www.scopus.com/pages/publications/84905370049

U2 - 10.1371/journal.pbio.1001906

DO - 10.1371/journal.pbio.1001906

M3 - Article

C2 - 25003521

AN - SCOPUS:84905370049

SN - 1544-9173

VL - 12

SP - 1

EP - 7

JO - PLoS Biology

JF - PLoS Biology

IS - 7

M1 - e1001906

ER -

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this